AUB ScholarWorks

Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR trial

Show simple item record

dc.contributor.author Taher A.
dc.contributor.author Al Jefri A.
dc.contributor.author Elalfy M.S.
dc.contributor.author Al Zir K.
dc.contributor.author Daar S.
dc.contributor.author Rofail D.
dc.contributor.author Baladi J.F.
dc.contributor.author Habr D.
dc.contributor.author Kriemler-Krahn U.
dc.contributor.author El-Beshlawy A.
dc.contributor.editor
dc.date May-2010
dc.date.accessioned 2017-10-05T15:39:30Z
dc.date.available 2017-10-05T15:39:30Z
dc.date.issued 2010
dc.identifier 10.1159/000313447
dc.identifier.isbn
dc.identifier.issn 00015792
dc.identifier.uri http://hdl.handle.net/10938/16913
dc.description.abstract Patient-reported outcomes of once-daily oral deferasirox (Exjade®) in iron-overloaded patients with β-thalassemia not achieving successful chelation with prior deferoxamine and-or deferiprone were investigated in a prospective, open-label, 1-year, multicenter study in the Middle East (ESCALATOR). The initial dose of deferasirox was 20 mg-kg-day, with subsequent dose adjustments. At baseline and the end of study (EOS), patients (n = 237) completed a 5-point rating scale for treatment satisfaction and convenience, and recorded time lost to treatment. At EOS, 90.7percent of patients were 'satisfied'-'very satisfied' with their iron chelation therapy (ICT) versus 23.2percent at baseline. 92.8percent (EOS) versus 21.5percent (baseline) of patients considered their therapy to be 'convenient'-'very convenient'. Time lost to therapy for daily activities was substantially reduced (3.2 ± 8.6 [mean ± SD; EOS] vs. 30.1 ± 44.2 [baseline] h-month). Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded β-thalassemia patients. © 2010 S. Karger AG, Basel.
dc.format.extent
dc.format.extent Pages: (220-225)
dc.language English
dc.publisher BASEL
dc.relation.ispartof Publication Name: Acta Haematologica; Publication Year: 2010; Volume: 123; no. 4; Pages: (220-225);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR trial
dc.type Article
dc.contributor.affiliation Taher, A., Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
dc.contributor.affiliation Al Jefri, A., King Faisal Specialist Hospital, Research Center, Riyadh, Saudi Arabia
dc.contributor.affiliation Elalfy, M.S., Ain Shams University, Cairo, Egypt
dc.contributor.affiliation Al Zir, K., National Thalassemia Center, Damascus, Syrian Arab Republic
dc.contributor.affiliation Daar, S., Sultan Qaboos University, Muscat, Oman
dc.contributor.affiliation Rofail, D., Mapi Values, Bollington, United Kingdom
dc.contributor.affiliation Baladi, J.F., Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
dc.contributor.affiliation Habr, D., Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
dc.contributor.affiliation Kriemler-Krahn, U., Novartis Pharma AG, Basel, Switzerland
dc.contributor.affiliation El-Beshlawy, A., Cairo University, Cairo, Egypt
dc.contributor.authorAddress Taher, A.; Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon; email: ataher@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail ataher@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Taher, A
dc.contributor.authorInitials Al Jefri, A
dc.contributor.authorInitials Elalfy, MS
dc.contributor.authorInitials Al Zir, K
dc.contributor.authorInitials Daar, S
dc.contributor.authorInitials Rofail, D
dc.contributor.authorInitials Baladi, JF
dc.contributor.authorInitials Habr, D
dc.contributor.authorInitials Kriemler-Krahn, U
dc.contributor.authorInitials El-Beshlawy, A
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Taher, A (reprint author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, Beirut 11072020, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Abetz L, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186-1477-7525-4-73; Alymara V, 2004, HEMATOL J, V5, P475, DOI 10.1038-sj.thj.6200550; Borgna-Pignatti C, 2005, ANN NY ACAD SCI, V1054, P40, DOI 10.1196-annals.1345.006; Cappellini MD, 2007, CLIN THER, V29, P909, DOI 10.1016-j.clinthera.2007.05.007; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Caro JJ, 2002, BMC BLOOD DISORD, V2, P4, DOI 10.1186-1471-2326-2-4; Delea TE, 2008, AM J HEMATOL, V83, P263, DOI 10.1002-ajh.21049; Fung EB, 2007, AM J HEMATOL, V82, P255, DOI 10.1002-ajh.20809; Giardina PJ, 2001, SEMIN HEMATOL, V38, P360, DOI 10.1016-S0037-1963(01)90030-7; Modell B, 2008, B WORLD HEALTH ORGAN, V86, P480, DOI 10.2471-BLT.06.036673; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056-NEJM199808133390701; Olivieri NF, 1997, BLOOD, V89, P739; POOLE JE, 1989, S AFR MED J, V75, P367; REBULLA P, 1990, HAEMATOLOGICA, V75, P122; Rofail D, 2009, VALUE HEALTH, V12, P109, DOI 10.1111-j.1524-4733.2008.00390.x; Taher A, 2009, EUR J HAEMATOL, V82, P458, DOI 10.1111-j.1600-0609.2009.01228.x; Taher A, 2009, HAEMATOL-HEMATOL J, V94, P82; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; Vichinsky E, 2008, ACTA HAEMATOL-BASEL, V119, P133, DOI 10.1159-000125550; Vidler V, 1998, Paediatr Nurs, V10, P17
dc.description.citedCount 17
dc.description.citedTotWOSCount 14
dc.description.citedWOSCount 14
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden ACHAA
dc.identifier.pubmedID 20424435
dc.identifier.scopusID 77951240325
dc.identifier.url
dc.publisher.address ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Acta Haematol.
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Acta Haematologica
dc.relation.ispartofPubTitleAbbr Acta Haematol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 123
dc.source.ID WOS:000278131800007
dc.type.publication Journal
dc.subject.otherAuthKeyword β-Thalassemia
dc.subject.otherAuthKeyword Convenience
dc.subject.otherAuthKeyword Deferasirox
dc.subject.otherAuthKeyword Iron chelation therapy
dc.subject.otherAuthKeyword Iron overload
dc.subject.otherChemCAS deferasirox, 201530-41-8
dc.subject.otherChemCAS deferiprone, 30652-11-0
dc.subject.otherChemCAS deferoxamine, 70-51-9
dc.subject.otherChemCAS iron, 14093-02-8, 53858-86-9, 7439-89-6
dc.subject.otherChemCAS Benzoic Acids
dc.subject.otherChemCAS Iron Chelating Agents
dc.subject.otherChemCAS Triazoles
dc.subject.otherChemCAS deferasirox
dc.subject.otherIndex deferasirox
dc.subject.otherIndex deferiprone
dc.subject.otherIndex deferoxamine
dc.subject.otherIndex iron
dc.subject.otherIndex absenteeism
dc.subject.otherIndex academic achievement
dc.subject.otherIndex adolescent
dc.subject.otherIndex adult
dc.subject.otherIndex article
dc.subject.otherIndex Asian
dc.subject.otherIndex beta thalassemia
dc.subject.otherIndex Caucasian
dc.subject.otherIndex child
dc.subject.otherIndex clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex daily life activity
dc.subject.otherIndex drug dose increase
dc.subject.otherIndex drug treatment failure
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex iron chelation
dc.subject.otherIndex iron overload
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex Middle East
dc.subject.otherIndex patient compliance
dc.subject.otherIndex patient satisfaction
dc.subject.otherIndex priority journal
dc.subject.otherIndex race difference
dc.subject.otherIndex rating scale
dc.subject.otherIndex school child
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Benzoic Acids
dc.subject.otherIndex beta-Thalassemia
dc.subject.otherIndex Child
dc.subject.otherIndex Child, Preschool
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Iron Chelating Agents
dc.subject.otherIndex Iron Overload
dc.subject.otherIndex Male
dc.subject.otherIndex Middle East
dc.subject.otherIndex Patient Satisfaction
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Triazoles
dc.subject.otherKeywordPlus SICKLE-CELL-DISEASE
dc.subject.otherKeywordPlus CHELATION-THERAPY
dc.subject.otherKeywordPlus REPORTED OUTCOMES
dc.subject.otherKeywordPlus DEFEROXAMINE
dc.subject.otherKeywordPlus SAFETY
dc.subject.otherKeywordPlus DEFERIPRONE
dc.subject.otherKeywordPlus ICL670
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account